Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-24-116768
Filing Date
2024-10-23
Accepted
2024-10-23 19:36:08
Documents
2
Period of Report
2024-10-21

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1530
2 EX-24 ikt-ex24.htm EX-24 17148
  Complete submission text file 0000950170-24-116768.txt   20163
Mailing Address C/O EPIRUS BIOPHARMACEUTICALS, INC. 699 BOYLSTON STREET, 8TH FLOOR BOSTON MA 02116
Business Address
Munshi Amit (Reporting) CIK: 0001612551 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39676 | Film No.: 241390327

Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Issuer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)